Why Novartis and Regeneron Care About This Tiny Biotech Stock | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 14 November, 2014 by The TZ Newswire Staff

Why Novartis and Regeneron Care About This Tiny Biotech Stock

Ophthotech’s Fovista may tip the scale in favor of either Novartis’ Lucentis or Regeneron’s Eylea.

See also
- Next Article 6 Reasons a Hasbro-DreamWorks Merger Is Risky
- Previous Article Caesars Entertainment’s Bankruptcy Deal: Is This a Scam?
Editorial Calender

November 2014

M T W T F S S

1 2

3 4 5 6 7 8 9

10 11 12 13 14 15 16

17 18 19 20 21 22 23

24 25 26 27 28 29 30

« Oct Dec »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar